

POLICY TITLE	INTERFERENTIAL CURRENT STIMULATION
POLICY NUMBER	MP-6.047

Original Issue Date (Created):	3/1/2012
Most Recent Review Date (Revised):	7/20/2018
Effective Date:	1/1/2019

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Interferential current stimulation is considered **investigational** as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Cross-references:

- MP-6.020** Transcutaneous Electrical Nerve Stimulation
- MP-6.050** Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy
- MP-2.064** Biofeedback and Neurofeedback Therapy

II. PRODUCT VARIATIONS

[TOP](#)

This policy is applicable to all programs and products administered by Capital BlueCross unless otherwise indicated below.

FEP PPO- Refer to FEP Medical Policy Manual MP-1.01.24 Interferential Stimulation for Treatment of Pain. The FEP Medical Policy manual can be found at:
<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

III. DESCRIPTION/BACKGROUND

[TOP](#)

Interferential current stimulation (IFS) is a type of electrical stimulation that has been investigated as a technique to reduce pain, improve function and range of motion, and treat gastrointestinal disorders.

IFS uses paired electrodes of 2 independent circuits carrying high-frequency and medium-frequency alternating currents. The superficial electrodes are aligned on the skin around the affected area. It is believed that IFS permeates the tissues more effectively and with less unwanted stimulation of cutaneous nerves, is more comfortable than transcutaneous

POLICY TITLE	INTERFERENTIAL CURRENT STIMULATION
POLICY NUMBER	MP-6.047

electrical nerve stimulation. There are no standardized protocols for the use of IFS; IFS may vary by the frequency of stimulation, the pulse duration, treatment time, and electrode-placement technique.

REGULATORY STATUS

A number of IFS devices have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process, including the Medstar™ 100 (MedNet Services) and the RS-4i® (RS Medical). IFS may be included in multimodal electrotherapy devices such as transcutaneous electrical nerve stimulation and functional electrostimulation.

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have musculoskeletal conditions who receive IFS, the evidence includes RCTs and meta-analyses. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. Placebo-controlled randomized trial(s) have found that IFS, when used to treat musculoskeletal pain and impaired function(s), does not significantly improve outcomes; additionally, a meta-analysis of placebo-controlled trials did not find a significant benefit of IFS for decreasing pain or improving function. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have gastrointestinal disorders who receive IFS, the evidence includes RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment related morbidity. IFS has been tested for a variety of gastrointestinal conditions, with a small number of trials completed for each condition. The results of the trials are mixed, with some reporting benefit and others not. This body of evidence is inconclusive on whether IFS is an efficacious treatment for gastrointestinal conditions. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have post stroke spasticity who receive IFS, the evidence includes an RCT. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The RCT had a small sample size and very short follow-up (immediately posttreatment). The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY TITLE	INTERFERENTIAL CURRENT STIMULATION
POLICY NUMBER	MP-6.047

V. DEFINITIONS

[TOP](#)

510 (K) is a premarketing submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent (SE), to a legally marketed device that is not subject to premarket approval (PMA). Applicants must compare their 510(k) device to one or more similar devices currently on the U.S. market and make and support their substantial equivalency claims.

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member's individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member's benefit information or contact Capital BlueCross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital BlueCross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Interferential Stimulation for the treatment of pain is investigational; therefore, the following codes are not covered when billed for interferential stimulation for treatment of pain:

CPT Codes®							
97014	97032						

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

POLICY TITLE	INTERFERENTIAL CURRENT STIMULATION
POLICY NUMBER	MP-6.047

HCPCS Code	Description
G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan
S8130	Interferential current stimulator, 2 channel
S8131	Interferential current stimulator, 4 channel

IX. REFERENCES

[TOP](#)

1. Zeng C, Li H, Yang T, et al. Electrical stimulation for pain relief in knee osteoarthritis: systematic review and network meta-analysis. *Osteoarthritis Cartilage*. Feb 2015;23(2):189-202. PMID 25497083
2. Fuentes JP, Armijo Olivo S, Magee DJ, et al. Effectiveness of interferential current therapy in the management of musculoskeletal pain: a systematic review and meta-analysis. *Phys Ther*. Sep 2010;90(9):1219-1238. PMID 20651012
3. Defrin R, Ariel E, Peretz C. Segmental noxious versus innocuous electrical stimulation for chronic pain relief and the effect of fading sensation during treatment. *Pain*. May 2005;115(1-2):152-160. PMID 15836978
4. Taylor K, Newton RA, Personius WJ, et al. Effects of interferential current stimulation for treatment of subjects with recurrent jaw pain. *Phys Ther*. Mar 1987;67(3):346-350. PMID 3493493
5. Atamaz FC, Durmaz B, Baydar M, et al. Comparison of the efficacy of transcutaneous electrical nerve stimulation, interferential currents, and shortwave diathermy in knee osteoarthritis: a double-blind, randomized, controlled, multicenter study. *Arch Phys Med Rehabil*. May 2012;93(5):748-756. PMID 22459699
6. Gundog M, Atamaz F, Kanyilmaz S, et al. Interferential current therapy in patients with knee osteoarthritis: comparison of the effectiveness of different amplitude-modulated frequencies. *Am J Phys Med Rehabil*. Feb 2012;91(2):107-113. PMID 22019968
7. Koca I, Boyaci A, Tutoglu A, et al. Assessment of the effectiveness of interferential current therapy and TENS in the management of carpal tunnel syndrome: a randomized controlled study. *Rheumatol Int*. Dec 2014;34(12):1639-1645. PMID 24728028
8. Lara-Palomo IC, Aguilar-Ferrandiz ME, Mataran-Penarrocha GA, et al. Short-term effects of interferential current electro-massage in adults with chronic non-specific low back pain: a randomized controlled trial. *Clin Rehabil*. May 2013;27(5):439-449. PMID 23035006
9. Facci LM, Nowotny JP, Tormem F, et al. Effects of transcutaneous electrical nerve stimulation (TENS) and interferential currents (IFC) in patients with nonspecific chronic low back pain: randomized clinical trial. *Sao Paulo Med J*. 2011;129(4):206-216. PMID 21971895
10. Albornoz-Cabello M, Maya-Martin J, Dominguez-Maldonado G, et al. Effect of interferential current therapy on pain perception and disability level in subjects with chronic low back pain: a randomized controlled trial. *Clin Rehabil*. Feb 2017;31(2):242-249. PMID 26975312

POLICY TITLE	INTERFERENTIAL CURRENT STIMULATION
POLICY NUMBER	MP-6.047

11. *Dissanayaka TD, Pallegama RW, Suraweera HJ, et al. Comparison of the effectiveness of transcutaneous electrical nerve stimulation and interferential therapy on the upper trapezius in myofascial pain syndrome: a randomized controlled study. Am J Phys Med Rehabil. Sep 2016;95(9):663-672. PMID 26945216*
12. *Kajbafzadeh AM, Sharifi-Rad L, Nejat F, et al. Transcutaneous interferential electrical stimulation for management of neurogenic bowel dysfunction in children with myelomeningocele. Int J Colorectal Dis. Apr 2012;27(4):453-458. PMID 22065105*
13. *Clarke MC, Chase JW, Gibb S, et al. Improvement of quality of life in children with slow transit constipation after treatment with transcutaneous electrical stimulation. J Pediatr Surg. Jun 2009;44(6):1268-1272; discussion 1272. PMID 19524752*
14. *Coban S, Akbal E, Koklu S, et al. Clinical trial: transcutaneous interferential electrical stimulation in individuals with irritable bowel syndrome - a prospective double-blind randomized study. Digestion. Aug 2012;86(2):86-93. PMID 22846190*
15. *Koklu S, Koklu G, Ozguclu E, et al. Clinical trial: interferential electric stimulation in functional dyspepsia patients - a prospective randomized study. Aliment Pharmacol Ther. May 2010;31(9):961-968. PMID 20136803*
16. *Suh HR, Han HC, Cho HY. Immediate therapeutic effect of interferential current therapy on spasticity, balance, and gait function in chronic stroke patients: a randomized control trial. Clin Rehabil. Sep 2014;28(9):885-891. PMID 24607801*
17. *Chou R, Atlas SJ, Stanos SP, et al. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. Spine (Phila Pa 1976). May 1 2009;34(10):1078-1093. PMID 19363456*
18. *American College of Occupational and Environmental Medicine (ACOEM). Shoulder disorders. In: Hegmann KT, ed. Occupational medicine practice guidelines. Evaluation and management of common health problems and functional recovery in workers. 3rd ed. Elk Grove Village, IL: ACOEM; 2011:1-297.*
19. *American College of Occupational and Environmental Medicine (ACOEM). Low Back Disorders. In: Hegmann KT, ed. Occupational medicine practice guidelines: evaluation and management of common health problems and functional recovery in workers. Westminster, CO: Reed Group; 2016:1-844.*
20. *American College of Occupational and Environmental Medicine (ACOEM). Knee Disorders. In: Hegmann KT, ed. Occupational medicine practice guidelines. Evaluation and management of common health problems and functional recovery in workers. 3rd ed. Elk Grove Village, IL: ACOEM; 2011:1-503.*
21. *Blue Cross Blue Shield Association Medical Policy Reference Manual. 1.01.24, Interferential Current Stimulation. June 2018.*

Other Sources:

Qaseem A, Wilt T, McLean R, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. April 4, 2017. [Website]: <http://annals.org/aim/article/2603228/noninvasive-treatments-acute-subacute-chronic-low-back-pain-clinical-practice>. Accessed July 20, 2018.

POLICY TITLE	INTERFERENTIAL CURRENT STIMULATION
POLICY NUMBER	MP-6.047

X. POLICY HISTORY

[TOP](#)

MP-6.047	CAC 10/25/2011 Adopted BCBSA. New Policy, information regarding interferential stimulation removed from Electrical Stimulation policy and created in this separate policy.
	CAC 10/30/12 Consensus. References updated. No change to policy statements. Codes reviewed 10/22/12
	CAC 11/26/13 Consensus review. References updated. “For the treatment of pain” removed from the policy statement however remains investigational. Rationale added. Policy title revised to “Interferential Current Stimulation”.
	CAC 11/25/14 Consensus. References and rationale updated. No change to policy statements. Coded Reviewed 11/05/2014
	CAC 11/24/15 Consensus review. No change to policy statements. Rationale and references updated. Coding reviewed.
	CAC 9/27/16 Consensus. No change to policy statements. References and rationale updated. Variation reformatted. Coding reviewed.
	CAC 11/28/17 Consensus. No change to policy statements. References and rationale reviewed. Coding reviewed.
	7/20/18 Consensus review. No change to the policy statement. Background and references updated. Rationale revised.
1/1/19 Admin Update: Removed deleted CPT codes	

[TOP](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.